Redhill Biopharma Ltd. current report, Q3 FY2016

Redhill Biopharma Ltd. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel, for the month of September 2016. The filing date is September 27, 2016. The document serves to incorporate by reference a press release announcing the company's presentation at the BioNetwork West 2016 Partnering Summit.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to disclose a corporate event rather than a financial statement.

Material Changes

No material financial changes versus the prior comparable period are disclosed in this document. The primary content is the announcement of an upcoming investor relations event.

Guidance, Outlook, and Risks

Management commentary is limited to the announcement of the presentation at the BioNetwork West 2016 Partnering Summit. The filing does not contain specific financial guidance, updated outlooks, new risk factors, contingencies, or unusual items. The press release is incorporated by reference into the company's Registration Statements on Form S-8 (filed May 2, 2013, and October 29, 2015) and Form F-3 (filed February 25, 2016).

Key Facts for Investor Verification

  • Verify the date and agenda of the BioNetwork West 2016 Partnering Summit presentation.
  • Review the full text of the incorporated press release for any strategic updates not detailed in the Form 6-K.
  • Confirm the status of the referenced Registration Statements (S-8 and F-3) for potential capital raising activities.
  • Note that this filing contains no new financial data; refer to the most recent Form 20-F for financial performance.